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Abstract 
 
Aims: To further characterize the neuropathology of the heterogeneous molecular 
disorder frontotemporal lobar degeneration (FTLD) with transactive response (TAR) 
DNA-binding protein of 43kDa (TDP-43) proteinopathy (FTLD-TDP). Methods: We 
quantified the neuronal cytoplasmic inclusions (NCI), glial inclusions (GI), neuronal 
intranuclear inclusions (NII), dystrophic neurites (DN), surviving neurons, 
abnormally enlarged neurons (EN), and vacuoles in regions of the frontal and 
temporal lobe using a phosphorylation independent TDP-43 antibody in thirty-two 
cases of FTLD-TDP comprising sporadic and familial cases, with associated 
pathology such as hippocampal sclerosis (HS) or Alzheimer’s disease (AD), and four 
neuropathological subtypes using TDP-43 immunohistochemistry. Analysis of 
variance (ANOVA) was used to compare differences between the various groups of 
cases.  Results: These data from FTLD-TDP cases demonstrate quantitative 
differences in pathological features between: (1) regions of the frontal and temporal 
lobe, (2) upper and lower cortex, (3) sporadic and progranulin (GRN) mutation cases, 
(4) cases with and without AD or HS, and (5) between assigned subtypes. 
Conclusions: The data confirm that the dentate gyrus is a major site of 
neuropathology in FTLD-TDP and that most laminae of the cerebral cortex are 
affected. GRN mutation cases are quantitatively different from sporadic cases while 
cases with associated HS and AD have increased densities of dystrophic neurites 
(DN) and abnormally enlarged neurons (EN) respectively. There is little correlation 
between the subjective assessment of subtypes and the more objective quantitative 
data.  
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List of abbreviations 
AD   Alzheimer’s disease 
ANOVA  Analysis of variance 
CA   Cornu Ammonis 
CBD   Corticobasal degeneration 
DN   Dystrophic neurites  
DG   Dentate gyrus 
EN   Abnormally enlarged neurons 
FTD   Frontotemporal dementia 
FTLD   Frontotemporal lobar degeneration 
FTLD-U Frontotemporal lobar degeneration with ubiquitin positive 
inclusions   
GI   Glial inclusions 
GRN   Progranulin (protein) 
GRN   Progranulin (gene) 
HDDD   Hereditary dysphasic disinhibition dementia 
IHC   Immunohistochemistry 
HS   Hippocampal sclerosis 
ITG   Inferior temporal gyrus 
MFG   Middle frontal gyrus 
MND   Motor neuron disease 
NCI   Neuronal cytoplasmic inclusion 
NII   Neuronal intranuclear inclusion 
NFT Neurofibrillary tangle 
PAX Progressive apraxia 
PHG Parahippocampal gyrus 
PNFA Progressive non-fluent aphasia 
PiD Pick’s disease 
SD Semantic dementia 
SP Senile plaque 
STG Superior temporal gyrus 
TDP-43 Transactive response (TAR) DNA-binding protein of 43kD  
UBAP1 Ubiquitin-associated binding protein 1 
VCP Valosin-containing protein 
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Introduction 
 
Frontotemporal lobar degeneration (FTLD) is the second most frequent form of 
cortical dementia of early-onset after Alzheimer’s disease (AD) [1]. The disorder is 
associated with a heterogeneous group of clinical syndromes including 
frontotemporal dementia (FTD), FTD with motor neuron disease (FTD-MND), 
progressive non-fluent aphasia (PNFA), semantic dementia (SD), and progressive 
apraxia (PAX) [2].  
 
FTLD with transactive response (TAR) DNA-binding protein of 43kDa (TDP-43) 
proteinopathy (FTLD-TDP), previously called FTLD with ubiquitin immunoreactive 
inclusions (FTLD-U) [3,4], is characterized by variable neocortical and allocortical 
atrophy principally affecting the frontal and temporal lobes. In addition, there is 
neuronal loss, microvacuolation in the superficial cortical laminae, and a reactive 
astrocytosis [5]. A variety of TDP-43 immunoreactive lesions are present in FTLD-
TDP including neuronal cytoplasmic inclusions (NCI), neuronal intranuclear 
inclusions (NII), dystrophic neurites (DN), and oligodendroglial inclusions (GI).  
 
FTLD-TDP is a heterogeneous molecular disorder [6]. First, there are sporadic and 
familial forms of the disease; the majority of the latter being caused by mutations in 
the progranulin (GRN) gene [7-14]. In addition, cases with valosin-containing 
protein (VCP) gene mutation [15], variants in the ubiquitin-associated binding 
protein 1 (UBAP1) gene [16,17], and common variants at the 7p21 locus have also 
been shown to be associated with FTLD with TDP-43 inclusions [18].  Second, 
FTLD can occur in combination with either MND (FTLD-MND), such cases often 
being associated with a more localized pattern of frontal lobe atrophy [19] or with 
hippocampal sclerosis (HS) [20], in which there is neuronal loss in the subiculum and 
sector CA1 of the hippocampus [21]. Some cases within the age range of FTLD-TDP, 
and especially those of later onset or expressing apoplipoprotein E (APOE) allele 4, 
exhibit varying degrees of AD pathology, viz. AD-type senile plaques (SP) and 
neurofibrillary tangles (NFT). A proportion of cases exhibit a degree of AD 
pathology greater than expected from normal aging [6]. Third, several attempts have 
been made to subtype FTLD-TDP [22-24]. Most schemes define four pathological 
subtypes, based originally on ubiquitin immunohistochemistry (IHC) but extended to 
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cases of FTLD-TDP, and which utilize the distribution and density of the 
pathological changes in neocortical regions. The same descriptors have been used to 
define subtypes but the numbering of each subtype varies between different schemes. 
Using a composite system proposed by Cairns et al. [24]: type 1 cases (Mackenzie-
type 2) are characterized by long DN in superficial cortical laminae with few or no 
NCI or NII, type 2 (Mackenzie-type 3) by numerous NCI in superficial and deep 
cortical laminae with infrequent DN and sparse or no NII, type 3 (Mackenzie-type 1) 
by pathology predominantly affecting the superficial cortical laminae with numerous 
NCI, DN and varying numbers of NII, and type 4 by numerous NII, and infrequent 
NCI and DN especially in neocortical areas.  
 
A previous study quantified the pathology in 94 cases of FTLD-TDP obtained from 
several academic centres [6] and principal components analysis (PCA) was used to 
compare the degree of similarity and dissimilarity between individual cases. To 
further characterize the neuropathology of this heterogeneous molecular disorder we 
quantified, in detail, the pathological changes in various regions of the frontal and 
temporal lobe in a subset of these cases, viz.,  thirty-two cases of FTLD-TDP 
obtained from a single academic centre (Alzheimer’s Disease Research Centre, 
Washington University School of Medicine, St Louis, Missouri, USA). The specific 
objectives were to compare the densities of the pathological changes between: (1) 
brain regions, (2) upper and lower cortex, (3) familial and sporadic cases, (4) cases 
with and without associated HS or AD pathology, and (5) assigned disease subtypes. 
In this study, analysis of variance (ANOVA) was used to compare the mean densities 
of histological features between the various groups of cases. 
. 
Materials and Methods 
 
Cases  
 
Thirty-two cases of clinically and neuropathologically well-characterized FTLD-TDP 
(16 male, 16 female) (see Table 1) were obtained from the Departments of Neurology 
and Pathology & Immunology, Washington University School of Medicine, St. 
Louis, MO., USA. All cases exhibited FTLD with neuronal loss, varying degrees of 
microvacuolation in the superficial cortical laminae, and a reactive astrocytosis 
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consistent with proposed diagnostic criteria for FTLD-TDP [24]. A variety of TDP-
43 immunoreactive lesions were present in these cases including NCI, NII, GI, and 
DN. Of the 32 cases, 20 were identified as familial (at least one or more first degree 
relatives affected) and of these, 10 cases were identified as having GRN mutations 
[7,8], one had a VCP gene mutation [15], and one case was associated with UBAP1 
[17], a presumptive gene on chromosome 9p21. The majority (N = 7) of the GRN 
cases come from a single hereditary dysphasic disinhibition dementia (HDDD) family 
(HDDD2) [9] and the remainder (N = 3) from the HDDD1 family. The genetic 
defects in the remaining familial cases (N = 8) have not been identified to date. None 
of the cases had coexisting MND (FTLD-MND) [25,26] but six were identified as 
having associated HS [20]. Identification of cases with additional AD pathology 
greater than that observed in normal aging [6] was based on Braak’s amyloid and 
NFT scores [27] which are themselves based on the topographical distribution of 
lesions in circumscribed areas of the limbic system and higher cortical areas. Cases 
with either an amyloid or NFT score of 4 or greater were considered to have 
associated AD pathology. Nine such cases were identified, five of which had both 
amyloid and NFT scores greater than 4 while four cases had only an NFT score 
greater than 4. Cases were assigned to the four subtypes of FTLD-TDP by an 
experienced neuropathologist, blind to cases details, based on the composite scheme 
of Cairns et al. [24]. To provide baseline data for comparison of the densities of 
surviving neurons, eight control cases, with no neurological or psychiatric histories, 
within the age range of the FTLD-TDP cases (61-80 years) were also studied. 
 
Histological methods  
 
After death, the consent of the next of kin was obtained for brain removal, following 
local Ethical Committee procedures (Human Studies Committee, Washington 
University School of Medicine) and the 1995 Declaration of Helsinki (as modified 
Edinburgh, 2000). Tissue blocks were taken from the frontal cortex at the level of the 
genu of the corpus callosum to study the middle frontal gyrus (MFG) and the 
temporal lobe at the level of the lateral geniculate body to study the inferior temporal 
gyrus (ITG), parahippocampal gyrus (PHG), CA1/2 sectors of the hippocampus, and 
dentate gyrus (DG). Tissue was fixed in 10% phosphate buffered formal-saline and 
embedded in paraffin wax. Following formic acid (95%) pretreatment for 5 minutes, 
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IHC was performed on 4 - 10µm sections with a rabbit polyclonal antibody (that 
recognizes TDP-43 (dilution 1:1000; ProteinTech Inc., Chicago, IL). Sections were 
also stained with haematoxylin. 
 
Both phosphorylation-dependent (pTDP-43) and independent (iTDP-43) antibodies 
have been used to study the TDP-43 immunoreactive pathological changes in FTLD-
TDP [28-31]. Initially we and many other groups used iTDP-43 which immunolabels 
normal physiological TDP-43 as well as pathological inclusions. This is a particularly 
useful attribute as this antibody shows clearly that in most neurons there is reduced 
staining in the nucleus and increased staining of the cytoplasm leading to the 
hypothesis that the protein is abnormally translocated in disease. However, it is often 
difficult to distinguish the presence of an abnormal inclusion, or pre-inclusion, in the 
nucleus, or even the cytoplasm where normal and abnormal staining may admix. The 
advantage of pTDP-43 antibodies is that they do not immunolabel normal 
physiological TDP-43 [28,31], especially in the nucleus, thus enabling the TDP-43-
immunoreactive lesions to be more clearly visualized and quantified. Nevertheless, 
studies suggest that the pTDP-43 immunoreactive lesions do not always co-localize 
with those revealed by iTDP-43 antibodies [30]. To address this question, we 
compared the densities of iTDP-43- and pTDP-43 immunoreactive lesions in sectors 
CA1/2 of the hippocampus using the Bland and Altman method [32] to compare the 
extent of the agreement between the two antibodies. 
 
Morphometric methods 
 
In the MFG, ITG, and PHG of each case, histological features were quantified along 
strips of tissue (1600 to 3200µm in length), located parallel to the pia mater, using 
between 32 and 64, 250 x 50µm sample fields arranged contiguously [33]. The 
sample fields were located both in the upper (approximating to laminae II/III) and 
lower (approximating to laminae V/VI) cortex; the short edge of the sample field 
being orientated parallel to the pia mater and aligned with guidelines marked on the 
slide. In the hippocampus, the features were counted in the cornu ammonis (CA) in 
sectors CA1 and CA2; the short dimension of the contiguous sample field being 
aligned with the alveus. NCI have been commonly observed in the DG fascia in 
FTLD-TDP [3,4,22] and a smaller sample field (50 x 50m) was aligned with the 
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upper edge of the granule cell layer. The data were then expressed per 250 x 50m 
sample field so that they were directly comparable with those from the other brain 
regions. The NCI [34,35, GI [36-41], NII [42] and DN [43] were counted in each 
sample field. Pre-inclusions were not included in the quantification.  Surviving 
neurons were identified as cells containing at least some stained cytoplasm in 
combination with larger shape and non-spherical outline [44]. By contrast, small 
spherical or asymmetrical nuclei without cytoplasm, but with the presence of a 
thicker nuclear membrane and more heterogeneous chromatin, were identified as glial 
cells. Abnormally enlarged neurons (EN) are a common feature of several 
neurodegenerative diseases. They are an important aspect of the pathology of 
tauopathies such as Pick’s disease (PiD) [45], corticobasal degeneration (CBD) [46], 
and argyrophilic grain disease (AGD) [47], and have also been described in 
Alzheimer’s disease (AD) [48]. EN in FTLD-TDP  were quantified according to the 
following criteria: (1) enlarged perikarya lacking NCI, (2) a shrunken nucleus 
displaced to the periphery of the cell, and (3) a maximum cell diameter of at least 
three times the diameter of the nucleus [44]. The EN in FTLD-TDP are not tau-
immunoreactive but it is not currently known whether they are immunoreactive to 
beta-crystallin. The number of discrete vacuoles greater than 5m in diameter was 
also recorded in each sample field [49,50].  
 
Data analysis 
 
The data were analyzed by analysis of variance (ANOVA) with subsequent 
comparisons between groups using Fisher’s ‘protected least significant difference’ 
(PLSD) post-hoc procedure (STATISTICA software, Statsoft Inc., 2300 East 14th St, 
Tulsa, Ok, 74104, USA). First, the densities of each histological feature in the upper 
cortical laminae of neocortical regions were compared with those in sectors CA1/2 
and the DG using a one-way ANOVA. A similar analysis was then carried out but 
substituting densities in the lower cortical laminae. Second, densities of each 
histological feature were compared between the upper and lower cortex using two-
factor, split-plot ANOVA with brain region as a main-plot factor and cortical laminae 
as the sub-plot factor. Third, the densities of each histological feature were compared 
initially between the sporadic cases and all familial cases using unpaired ‘t’ tests, and 
then between the cases divided into four subgroups, viz., 1) sporadic cases, 2) cases 
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with GRN mutation, 3) cases with other mutations (VCP, CH9), and 4) the remaining 
undetermined familial cases; the groups being compared by a one-way ANOVA. 
There were no differences between GRN mutation cases originating from the HDDD1 
and HDDD2 families and these cases were analyzed as a single group. Fourth, 
densities were compared between cases divided into three subgroups based on the 
presence of associated pathology, viz., 1) FTLD-TDP with HS, 2) FTLD-TDP with 
AD pathology, and 3) FTLD-TDP without any apparent associated pathology. In 
addition, densities were compared between the four subtypes of the disease based on 
the composite scheme of Cairns et al. [24]. 
 
Results 
 
Typical examples if the TDP-43-immunoreactive inclusions are shown in Figs 1a-c. 
The NCI (Fig 1a) were round or spicular in shape[34,35], while the GI (Fig 1a) 
morphologically resembled the ‘coiled bodies’ reported in various tauopathies such as 
corticobasal degeneration (CBD) [36,37], progressive supranuclear palsy (PSP) [37-
39], and argyrophilic grain disease (AGD) [41]. The NII (Fig 1b) were often 
lenticular, spindle-shaped, or circular in shape [42] and the DN (Fig 1a) were 
characteristically long and contorted [43]. A typical example of EN in FTLD-TDP is 
shown in Fig 1c. 
 
A comparison of the densities of TDP-43-immunoreactive inclusions in sectors 
CA1/2 of the hippocampus in sections immunolabelled with iTDP-43 and pTDP-43 
antibodies is shown in Table 2. For the NCI, the overall mean bias was +0.22 (SD = 
0.31, CV 0.62). Hence, on average the pTDP-43 antibody revealed +0.22 more NCI 
per sample field than iTDP-43. For the GI, the mean bias was +0.09 and thus pTDP-
43 revealed slightly more GI per plot. For the NII, the mean bias was –0.12 and thus 
on average pTDP-43 revealed 0.12 fewer lesions than the iTDP-43 antibody. For the 
DN, the errors were symmetrically distributed approximately around zero (mean bias 
was –0.04) and therefore very similar densities of DN were revealed by both 
antibodies. 
 
The densities of the TDP-43-immunoreactive lesions in each brain region, averaged 
over the thirty-two cases, are shown in Fig 2. Significant differences in density of 
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NCI were observed between regions when both the upper (F = 7.43, P < 0.001) and 
lower (F = 9.46, P < 0.001) cortex data were included in the analysis. When densities 
of NCI in the upper cortex were compared with sectors CA1/2 and the DG, densities 
were greater in the DG compared with all other regions. In addition, the density of 
NCI was significantly greater in the MFG compared with CA1/2. Results were 
similar when lower cortex data were substituted in the analysis. Apart from the DG, 
in which no GI were recorded, there were no significant differences in GI density 
between regions. Significant differences in the density of NII were observed between 
regions in the upper (F = 2.91, P < 0.05) and lower (F = 3.23, P < 0.05) cortex. When 
densities in the upper cortex were compared with sectors CA1/2 and the DG, 
densities were significantly lower in the DG compared with the CA1/2 and the MFG. 
There were significant differences in the density of DN between regions in the upper 
cortex only (F = 3.14, P < 0.05). In addition, the density of DN was significantly 
lower in the DG compared with all neocortical regions.  
 
The mean densities of the vacuolation, surviving neurons, and EN in each brain 
region, averaged over cases, are shown in Fig 3. There were significant variations in 
the density of vacuoles between regions in the upper (F = 8.34, P < 0.001) and lower 
(F = 2.95, P < 0.05) cortex. There were no significant differences in the density of 
surviving neurons between neocortical gyri. There were significant variations in the 
density of EN between regions in the upper (F = 7.18, P < 0.001) and lower (F = 
10.52, P < 0.05) cortex. When densities in the upper cortex were analyzed, the 
density of the EN was lower in the MFG than the ITG but greater than in the DG.  In 
addition, densities of the EN were greater in CA1/2 compared with the ITG, PHG, 
and DG. Similar results were obtained when lower cortical data were substituted in 
the analysis except that the density of vacuoles was significantly lower in the DG but 
only when compared with the MFG. 
 
The mean densities of surviving neurons in regions of frontal and temporal lobe in the 
control cases studied are shown in Table 3. Compared with controls, the FTLD-TDP 
cases collectively show approximately similar reductions in neurons in each of the 
brain regions examined. 
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A comparison of the densities of histological features between upper and lower cortex 
using two-factor ANOVA is shown in Table 4. In all regions, the densities of NCI (F 
= 7.41, P < 0.01), DN (F = 10.27, P < 0.01), and vacuoles (F = 35.24, P < 0.001) were 
greater in the upper cortex while the density of NII (F = 6.35, P < 0.01) was greater in 
the lower cortex. There were no significant differences in the densities of the GI or 
surviving neurons between the upper and lower cortex. The distribution of EN was 
more complex; a significant cortical laminae/region interaction (F = 5.59, P < 0.01) 
suggesting that densities of EN were greater in the upper cortex in the MFG but in the 
lower cortex in the ITG. 
 
A comparison of familial and sporadic FTLD-TDP cases is shown in Table 5. There 
were no significant differences in the density of histological features between 
sporadic cases and the familial cases taken as a whole. When cases were divided into 
four subgroups, however, the density of NCI was greater in the MFG of the GRN 
mutation cases and in cases caused by VCP and CH9, compared with the sporadic and 
undetermined familial cases (F = 3.12, P < 0.05). Moreover, the densities of the 
vacuoles (F = 4.03, P < 0.05) and DN (F = 3.47, P < 0.05) were greater in the GRN 
cases compared with the other familial cases and the sporadic cases. In the DG, there 
were greater numbers of surviving granule cells in the GRN mutation cases compared 
with the other patient groups (F = 4.31, P < 0.05).  
 
A comparison of the densities of histological features in FTLD-TDP cases with and 
without associated HS or AD pathology is shown in Table 6. In the upper cortex of 
the MTG, there were greater densities of EN (F = 4.62, P < 0.05) in cases with 
significant AD pathology. In addition, in the upper cortex of the ITG, there were 
greater densities of DN (F = 3.84, P < 0.05) in cases with associated HS and in 
sectors CA1/2 of the hippocampus, greater densities of NCI in cases with associated 
AD pathology (F = 4.05, P < 0.05). 
 
A comparison of the densities of histological features in the FTLD-TDP cases 
assigned to the four subtypes is shown in Table 7. There were no significant 
differences between subtypes in the densities of GI or DN in any of the brain regions 
studied, and in sectors CA1/2 and the DG, no differences in density of any of the 
pathological features with subtype. There were, however, significant differences in 
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the density of NCI between subtypes in three regions. Hence, in the upper cortex of 
the MFG (F = 3.25, P < 0.05), greater densities of NCI were present in subtype 2 
compared with subtype 1, in the upper cortex of the ITG (F = 4.49, P < 0.05), greater 
densities in subtypes 2 and 3 compared with subtypes 1 and 4, and in the lower cortex 
of the ITG (F = 6.16, P < 0.01), the greatest densities were observed in subtype 2.  In 
addition, there were significant differences in the density of NII between subtypes in 
three brain regions. In the lower cortex of the MFG (F = 3.38, P < 0.05) and PHG (F 
= 5.57, P < 0.01), and the upper cortex of the ITG (F = 3.53, P < 0.05), the greatest 
densities of NII were observed in subtype 4. There were also significant differences 
in vacuolation between subtypes in 3 regions, with greater densities of vacuoles in 
subtype 1, and of surviving neurons, EN and subtype each in a single brain region. 
 
Discussion 
 
The objective of this study was to characterize quantitatively the neuropathological 
differences between brain regions, upper and lower cortex, familial and sporadic 
cases, cases with and without associated HS or AD pathology, and to further consider 
the validity of disease subtyping in a group of 32 FTLD-TDP cases obtained from a 
single academic centre. This particular group of cases contained an unusually high 
percentage of familial cases and the majority of these were from the HDDD2 family. 
 
Some differences were observed in the densities of lesions in sectors CA1/2 of the 
hippocampus observed using iTDP-43 and pTDP-43 antibodies. Lesions are easier to 
observe using the pTDP-43 antibody and therefore the densities of NCI and GI may 
have been underestimated using the iTDP-43 antibody. By contrast, fewer NII were 
recorded using the pTDP-43 antibody suggesting that they have been overestimated 
using iTDP-43. However, whether or not all TDP-43 immunoreactive lesions are 
phosphorylated and the significance of phosphorylation in the development of TDP-
43 pathology in FTLD-TDP remains to be established [29]. 
 
In the FTLD-TDP cases as a whole, there were quantitative differences in the density 
of several histological features between brain regions. First, the greatest densities of 
NCI were observed in the DG, densities often being significantly lower in the 
adjacent sectors CA1/2 of the hippocampus and the PHG; thus confirming the DG as 
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a significant site of temporal lobe pathology in FTLD-TDP [3,4,22]. By contrast, 
densities of the NII were usually greater in the frontal and temporal neocortex and in 
sectors CA1/2 of the hippocampus while DN were most abundant in the neocortex; 
densities of both lesions being low in the DG. The GI exhibited the lowest densities 
of the TDP-43-immunoreactive inclusions recorded and apart from the DG, exhibited 
no apparent regional preference. The density of EN was low in the FTLD-TDP cases 
generally and significantly lower than reported in various tauopathies such as 
corticobasal degeneration (CBD) [37], and Pick’s disease (PiD) [51]. By contrast, 
vacuolation [49,50] was a consistent feature of neocortical regions, especially of the 
upper cortex, densities being significantly lower in the lower cortex and in the 
hippocampus.  
 
Differences in the density of various pathological features were also observed 
between upper and lower cortical laminae. The NCI and DN, for example, were 
present at higher densities in the upper cortex and NII in the lower cortex suggesting 
that degeneration occurs across the cortex in FTLD-TDP; the NCI/DN and NII 
affecting different populations of neurons. The relative distributions of the vacuoles 
and surviving neurons suggest it is the upper cortex that is affected to the greatest 
extent. In addition, there were no significant differences in the density of surviving 
neurons in the upper and lower cortex. In association cortex of normal brain, the 
distribution of the larger pyramidal neurons across the cortex is often double-peaked 
(bimodal); the two peaks of density corresponding spatially to laminae II/III and V/VI 
with the larger of the two density peaks in the upper cortex [37]. Hence, the similarity 
in the density of neurons in the upper and lower cortex in our cases is also consistent 
with a greater neuronal loss affecting the upper laminae in FTLD-TDP. 
 
Differences in density of various pathological features were observed between 
familial and sporadic cases of FTLD-TDP. The majority of the familial cases in the 
present study had GRN mutations from the HDDD2 family [9]. These GRN cases had 
consistently higher densities of NCI, DN, and vacuoles in the MFG compared with 
the sporadic cases. Previous studies report that DN were more frequent in the frontal 
cortex and less frequent in the DG in GRN cases consistent with our data [43,52]. In 
addition, cases lacking GRN mutations may have a less severe pathology affecting the 
neocortex and striatum while NII are usually absent or infrequent [10]. The density of 
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NII, however, was statistically similar in our sporadic and familial cases but greater 
neuronal preservation was suggested within the DG in the GRN cases. 
 
In FTLD-TDP cases with HS, significantly higher densities of DN were recorded in 
the ITG, while cases with significant AD pathology had higher densities of EN in the 
MTG and NCI in sectors CA1/2 of the hippocampus. HS is usually associated with 
enhanced neuronal loss in the subiculum and sector CA1 of the hippocampus [21] but 
there were no differences in the density of surviving neurons in these regions in the 
present cases with or without HS. Moreover, the density of EN was low in our FTLD-
TDP cases [6] but the data did suggest that increased densities of EN could be 
associated with the presence of enhanced AD pathology. The increase in the density 
of TDP-43-immunoreactive NCI in sectors CA1/2 of the hippocampus in cases with 
associated AD pathology is also of interest as large numbers of NFT occur in these 
sectors in ‘pure’ AD [53]. Hence, in FTLD-TDP with associated AD pathology, a 
proportion of the NCI in sectors CA1/2 could be AD-NFT but with the inclusions 
having acquired TDP-43 immunoreactivity [54].  
 
Several authors have attempted to divide FTLD-TDP cases into pathological 
‘subtypes’ [22-24] and many continue to find the classification sufficiently robust to 
differentiate cases effectively. In the multicentre study of Cairns et al. [5], for 
example, the majority of the GRN mutation cases were assigned to subtype 3 and 
VCP to subtype 4. In the present study, in which subtypes were assigned blind to the 
details of the cases, although some GRN mutation cases were assigned to subtype 3, 
subtypes 1, 2 and 4 were also represented. Quantitative differences were observed 
between the cases assigned to the various subtypes and especially greater densities of 
NCI in subtype 2 and NII in subtype 4, but these are subtle quantitative differences 
rather than the large qualitative variations necessary for ease of subtyping. In 
addition, quantitative differences between subtypes were not consistently present in 
different brain regions. The previous quantitative study of 94 FTLD-TDP cases from 
several centres, and which included the present cases, showed that apart from the 
subtype 1 cases which did appear to more distinct, the FTLD-TDP cases formed a 
‘continuum’ and there was broad overlap between the subtypes, especially between 
subtypes 2 and 3. The original classification schemes were based on ubiquitin IHC, 
on the relative numbers of lesions, and on their laminar distribution. Hence, although 
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the classification scheme has been extended to include TDP-43 IHC, quantitative 
pathological information based on TDP-43 IHC may have added complexity or noise 
to the data. Overall there remains little correlation between the subjective assessment 
of subtypes assigned blind to the details of the cases and the more objective 
quantitative data. This discrepancy may depend on (1) the cases studied may have 
been especially difficult to assign to subtype, (2) a restricted number of brain regions 
were sampled and hence, a better correlation might have been obtained if the 
quantitative study was extended to the motor cortex, basal ganglia, amygdala, 
midbrain, and medulla, (3) the skill and experience of neuropathologists involved in 
subtyping, and (4) the use of the iTDP-43 antibody. To clarify this question further, it 
would be useful to conduct a large-scale study of FTLD-TDP cases to assess inter-
rater reliability in assigning the four subtypes.  
 
In conclusion, significant variations in TDP-43 pathology were observed between 
regions in the frontal and temporal lobe; the greatest densities of NCI being recorded 
in the DG, NII in the lower cortex and in sectors CA1/2 of the hippocampus, and DN 
in the upper cortex. Cases caused by GRN mutations may be associated with greater 
densities of NCI, DN, and vacuoles in some areas while cases with associated HS or 
with significant AD pathology also show differences in density. There are some 
differences in density of NCI and NII between disease subtypes but these do not 
provide an objective basis for subtyping. The classification of FTLD-TDP cases as a 
whole is under review and new variations and subtypes of the disease are likely to be 
proposed and therefore, detailed quantitative data and analysis may be of value in 
elucidating this complex molecular pathology. 
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Table 1. Summary of demographic features (M/F = Male/female, Dur = Disease 
duration, Death = Age at death), gross brain weight (BW), familial/sporadic status 
(Fm/S) (GRN = FTLD-TDP with progranulin gene mutations, (1) indicates HDDD1 
family and (2) HDDD2 family; VCP = FTLD-TDP with valosin-containing protein, 
CH9 = FTLD-TDP linked to a putative gene on chromosome 9), associated pathology 
(AP) (N = no associated pathology, HS = hippocampal sclerosis, AD = significant 
Alzheimer’s disease pathology), pathological subtype (ST) (ND = subtype could not 
be determined, 1/2 = case intermediate between subtype 1 and 2) of the 32 cases of 
 24
frontotemporal lobar degeneration with TDP proteinopathy (FTLD-TDP), (- data not 
available). 
_____________________________________________________________________ 
Case  M/F Onset Dur Death BW Fm/S  AP ST 
  
1.  M 57 8 65 960 S  N 2  
2.  F 72 12 84 900 S  HS 2  
3.  F 61 16 77 950 S  N 3  
4.  F 68 6 74 975 GRN (2) N 4  
5.  M 52 13 65 1300 Fm  AD 1  
6.  M 66 16 82 - S  HS 3  
7.  F 69 15 84 970 GRN (1) AD 3  
8.  M 60 6 66 - GRN (1) AD 1  
9.  F 65 12 77 810 GRN (1) N 1  
10.  M 52 15 67 960 GRN (2) N 4  
11.  M 74 6 80 1270 GRN (2) AD 4  
12.  F - - 67 990 S  N 2  
13.  F 59 9 68 650 Fm  N 2  
14.  M 74 1 75 1360 S  N 1  
15.  M 60 11 71 1450 Fm  HS 4  
16.  M 43 7 50 1060 Fm  N 3  
17.  M 55 11 66 1005 S  HS 2  
18.  F 63 3 66 950 S  N 1  
19.  F 58 9 67 880 GRN (2) HS 2  
20.  F 64 19 83 720 Fm  N 1/2  
21.  F 69 4 71 1070 S  N 4  
22.  M 38 9 47 1185 VCP  N 4  
23.  F - - 73 720 S  N 1  
24.  M 50 18 68 1170 S  HS 1  
25.  M 58 8 66 1080 Fm  AD 4  
26.  F 65 13 78 960 Fm  N ND  
27.  M 57 6 63 1080 GRN (2) N 3  
28.  M 51 11 62 880 CH9  AD 2  
29.  F 71 13 84 960 S  AD 1  
 25
30.  F 73 9 82 - GRN (2) AD 2  
31.  F 58 8 66 - Fm  N 4  
32.  M 71 8 79 1150 GRN (2) AD 3  
_____________________________________________________________________
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Table 2. Summary of the degree of agreement between the densities of the TDP-43 
immunoreactive lesions (NCI = Neuronal cytoplasmic inclusions, GI = Glial 
inclusions, NII = Neuronal intranuclear inclusions, DN = Dystrophic neurites) in the 
CA sectors of the hippocampus using phosphorylation-dependent (pTDP-43) and 
phosphorylation-independent (iTDP-43) antibodies using the Bland and Altman 
graphical method (SD = Standard deviation, CV = Coefficient of variation). 
_____________________________________________________________________ 
Lesion  Bias  SD CV  Limits of agreement 
      
NCI  +0.22  0.31 0.62  -0.39 to 0.84 
GI  +0.09  0.24 0.48  -0.39 to 0.57 
NII  -0.12  0.21 0.42  -0.54 to 0.29 
DN  -0.04  0.34 0.66  -0.70 to 0.63 
_____________________________________________________________________ 
 27
Table 3. Mean densities of surviving neurons (250 x 50m field) in regions of the 
frontal and temporal lobe (MFG = Middle frontal gyrus, ITG = Inferior temporal 
gyrus, PHG = Parahippocampal gyrus, CA1/2 = Sectors CA1/2 of the hippocampus, 
DG = Dentate gyrus) in control cases (SE = Standard error of the mean) 
 
    Brain region 
_____________________________________________________________________ 
 MFG  ITG  PHG  CA1/2  DG 
 
Mean 9.55  8.33  8.14  4.89  18.18 
SD 1.08  2.07  1.30  1.06  3.09 
_____________________________________________________________________
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Table 4. Summary of the results of two-factor analyses of variance (ANOVA) of the 
densities of histological features (NCI = neuronal cytoplasmic inclusions, GI = 
oligodendroglial inclusions, NII = neuronal intranuclear inclusions (NII), EN = 
abnormally enlarged neurons, SN = surviving neurons, V = vacuolation, DN = 
dystrophic neurites) in the upper and lower cortex in cases of frontotemporal lobar 
degeneration with TDP-43 proteinopathy (FTLD-TDP) (Data are ‘F’ ratios from two 
factor, split-plot analysis of variance  (ANOVA) * P < 0.05; ** P < 0.01; *** P < 
0.001). 
 
    Factorial effect 
_____________________________________________________________________ 
Histological Brain region  Upper/Lower cortex Interaction 
feature 
 
NCI  F = 0.62  F = 7.41**  F = 0.11  
GI  F = 1.50  F = 1.82  F = 0.12  
NII  F = 0.56  F = 6.35**  F = 0.20  
EN  F = 0.54  F = 1.15  F = 5.59**  
SN  F = 2.68  F = 3.79  F = 0.38 
V  F = 1.12  F = 35.24***  F = 1.56  
DN  F = 0.27  F = 10.27**  F = 0.85 
_____________________________________________________________________ 
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Table 5. Comparison of the densities (per 50 x 250m field, standard errors in 
parentheses) of the pathological changes (NCI = neuronal cytoplasmic inclusions, DN 
= dystrophic neurites) between familial (GRN = cases caused by progranulin 
mutations) and sporadic cases of frontotemporal lobar degeneration with TDP-43 
proteinopathy  (FTLD-TDP). Data show brain areas (MFG = Middle frontal gyrus, 
DG = dentate gyrus) and pathological features that exhibit a significant difference 
between groups. 
 
      FTLD-TDP group 
_____________________________________________________________________ 
Brain  Histological Sporadic GRN  Other  Other 
region  feature  cases  mutation mutation familial 
      cases  cases  cases 
 
MFG  NCI  0.12 (0.05) 0.36 (0.06) 0.22 (0.13) 0.14 (0.06) 
(upper  
cortex) 
  Vacuoles 8.87 (1.82) 16.75 (2.02) 5.38 (4.26) 9.26 (1.91) 
 
  DN  0.29 (0.15) 0.78 (0.17) 0  0.08 (0.16) 
 
DG  Surviving  13.42 (0.86) 17.49 (0.09) 14.12 (2.02) 13.4 (0.91) 
  neurons 
_____________________________________________________________________ 
ANOVA (1-way): MFG, NCI F = 3.12 (P < 0.05); Vacuoles F = 4.03 (P < 0.05); DN, 
F = 3.47 (P < 0.05); DG, Surviving neurons F = 4.31 (P < 0.01). 
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Table 6. Comparison of the densities (per 50 x 250m field, standard errors in 
parentheses) of the pathological changes (NCI = neuronal cytoplasmic inclusions, DN 
= dystrophic neurites, EN = abnormally enlarged neurons) between cases with and 
without associated pathologies (AP) (AD = with significant Alzheimer’s disease 
pathology, HS = Hippocampal sclerosis) in cases of frontotemporal lobar 
degeneration with TDP-43 proteinopathy  (FTLD-TDP). Data show brain regions 
(MFG = Middle frontal gyrus, ITG = Inferior temporal gyrus) and pathological 
features that exhibit a significant difference between groups. 
 
      Patient group 
_____________________________________________________________________ 
Brain Region  Pathological No AP  FTLD/AD FLTD/HS 
feature 
 
MFG (upper  EN  0.08 (0.03) 0.24 (0.04) 0.07 (0.05) 
cortex)   
  
ITG (upper  DN  0.33 (0.14) 0.17 (0.19) 0.99 (0.23) 
cortex) 
   
Sectors CA1/2  NCI  0.03 (0.02) 0.13 (0.03) 0.03 (0.04) 
_____________________________________________________________________ 
ANOVA (1-way): MFG, EN: F = 4.62 (P < 0.05); ITG, DN: F = 3.84 (P < 0.05); DN: 
F = 3.47 (P < 0.05), CA1/2, NCI: F = 4.05 (P < 0.05). 
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Table 7. Comparison of the densities (per 50 x 250m field, standard errors in 
parentheses) of the pathological changes (NCI = neuronal cytoplasmic inclusions, NII 
= neuronal intranuclear inclusions, SN = surviving neurons, EN = abnormally 
enlarged neurons) between the four subtypes of frontotemporal lobar degeneration 
with TDP-43 proteinopathy  (FTLD-TDP) based on the composite scheme of Cairns 
et al (2007b). Data show brain regions (MFG = Middle frontal gyrus, ITG = Inferior 
temporal gyrus, PHG = parahippocampal gyrus) and pathological features that exhibit 
a significant difference between groups. 
      Subtype 
_____________________________________________________________________ 
Brain region Pathological 1  2  3  4 
feature 
 
MFG (upper NCI  0.06 (0.04) 0.37 (0.06) 0.28 (0.08) 0.15 (0.07) 
cortex) 
MFG (lower NII  0.19 (0.06) 0.18 (0.06) 0.13 (0.06) 0.39 (0.06) 
cortex)    
ITG (upper NCI  0.08 (0.05) 0.29 (0.05) 0.28 (0.06) 0.10 (0.05) 
cortex)  NII  0.04 (0.02) 0.08 (0.03) 0.09 (0.06) 0.32 (0.07)
  SN  5.03 (0.71) 6.45 (0.73) 7.82 (0.93) 3.67 (0.71) 
  Vacuoles 10.53 (1.24) 8.46 (1.24) 10.11 (1.57) 5.30 (1.24) 
ITG (lower NCI  0.06 (0.03) 0.31 (0.05) 0.02 (0.01) 0.04 (0.02) 
Cortex  Vacuoles 10.26 (0.70) 2.30 (0.69) 6.21 (0.77) 5.45 (0.69) 
PHG (upper Vacuoles  16.31 (1.78) 6.36 (1.75) 10.34 (2.27) 6.81 (1.80) 
cortex) 
PHG (lower NII  0.05 (0.03) 0.20 (0.06) 0.26 (0.08) 0.42 (0.06) 
cortex) 
Sectors CA1/2  EN  0.15 (0.04) 0.05 (0.04) 0.22 (0.04) 0.07 (0.04) 
____________________________________________________________________ 
ANOVA (1-way): MFG-upper, NCI: F = 3.35 (P < 0.05) Subtype 2 > 1 and 2 > 4; 
MFG-lower NII F = 3.40 (P < 0.05), Subtype 4 >1,2,3; ITG-U, NCI: F = 4.51 (P < 
0.05), Subtype 2,3 > 1,4; NII F = 3.53 (P < 0.05), Subtype 4 >1,2,3; SN F = 4.35 ( P < 
0.05), Subtype 2,3 > 1,4; Vacuoles F = 3.46 (P< 0.05), Subtype 1,3 > 4; ITG-lower 
NCI F = 7.21 (P < 0.01), subtype 2 > 1,3,4; Vacuoles F = 5.46 (P < 0.01), Subtype 1 
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> 2,4; PHG-upper Vacuoles F = 5.01 (P < 0.01), Subtype 1 > 2,4; PHG-lower NII F = 
5.57 (P < 0.01), Subtype 4 > 1,2; CA1/2 EN F = 3.77 (P < 0.05), Subtype 3 > 2,4. 
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Legends to figures 
 
Fig 1a. Frontotemporal lobar degeneration with TDP-43 proteinopathy  (FTLD-
TDP). TDP-43 immunoreactive lesions in the frontal cortex showing neuronal 
cytoplasmic inclusion (NCI) (arrow), dystrophic neurite (DN) (double arrow), and 
glial inclusion (GI) (arrow head) (TDP-43 immunohistochemistry, bar = 50m). 
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Fig 1b. Frontotemporal lobar degeneration with TDP-43 proteinopathy  (FTLD-
TDP). Neuronal intranuclear inclusion (NII) in lamina III of the superior temporal 
gyrus (TDP-43 immunohistochemistry, bar = 10m). 
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Fig 1c. Frontotemporal lobar degeneration with TDP-43 proteinopathy  (FTLD-TDP). 
Abnormally enlarged neuron (EN) (arrows) in lamina III of the superior temporal 
gyrus (H/E, bar = 20m). 
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Fig 2. Mean densities (error bars indicate standard errors) of the TDP-43 
immunoreactive pathological features (NCI = neuronal cytoplasmic inclusions, GI = 
oligodendroglial inclusions, NII = neuronal intranuclear inclusions (NII), DN = 
dystrophic neurites,) in the frontal and temporal lobe (MFG = Middle frontal gyrus, 
ITG = Inferior temporal gyrus, PHG = Parahippocampal gyrus, CA1/2 = Sectors 
CA/2 of the hippocampus, DG = Dentate gyrus), U = Upper cortex, L = lower cortex) 
of cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-
TDP). Analysis of variance (1-way): 1) Comparing upper cortex, CA1/2, and DG 
data: NCI, F = 7.43 (P < 0.001); GI, F = 3.71 (P < 0.01); NII, F = 2.91 (P < 0.05); 
DN, F = 3.14 (P < 0.05); 2) Comparing lower cortex, CA1/2, and DG data: NCI, F = 
9.46 (P < 0.001); GI, F = 3.54 (P < 0.01); NII, F = 3.23 (P < 0.05); DN F = 2.08 (P > 
0.05).  
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Fig 3. Mean densities (error bars indicate standard errors) of the vacuolation, 
surviving neurons, and enlarged neurons (EN) in the frontal and temporal lobe  (MFG 
= Middle frontal gyrus, ITG = Inferior temporal gyrus, PHG = Parahippocampal 
gyrus, CA1/2 = Sectors CA/2 of the hippocampus, DG = Dentate gyrus), U = Upper 
cortex, L = lower cortex) of cases of frontotemporal lobar degeneration with TDP-43 
proteinopathy (FTLD-TDP). Analysis of variance (1-way): 1) Comparing upper 
cortex, CA1/2, and DG data, Vacuoles F = 8.34 (P < 0.001), Surviving neurons = 
131.97 (P < 0.001), EN F = 7.18 (P < 0.001); 2) Comparing lower cortex, CA1/2, DG 
data: Vacuoles F = 2.95 (P < 0.05), Surviving neurons F = 166.89 (P < 0.001), EN F 
=10.52 (P < 0.001).  
 
 
